As China's biopharma sector races forward, investors are setting their sights on three vibrant innovation hotspots for 2026: Beijing, Shanghai, and Shenzhen. These energetic hubs are driving revolutionary breakthroughs, drawing substantial investment, and igniting rapid market expansion in this fast-moving industry